Literature DB >> 19185083

From randomized controlled trials to observational studies.

Stuart L Silverman1.   

Abstract

Randomized controlled trials are considered the gold standard in the hierarchy of research designs for evaluating the efficacy and safety of a treatment intervention. However, their results can have limited applicability to patients in clinical settings. Observational studies using large health care databases can complement findings from randomized controlled trials by assessing treatment effectiveness in patients encountered in day-to-day clinical practice. Results from these designs can expand upon outcomes of randomized controlled trials because of the use of larger and more diverse patient populations with common comorbidities and longer follow-up periods. Furthermore, well-designed observational studies can identify clinically important differences among therapeutic options and provide data on long-term drug effectiveness and safety.

Entities:  

Mesh:

Year:  2009        PMID: 19185083     DOI: 10.1016/j.amjmed.2008.09.030

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  100 in total

1.  Combined stimulant and antipsychotic treatment in adolescents with attention-deficit/hyperactivity disorder: a cross-sectional observational structural MRI study.

Authors:  L J S Schweren; C A Hartman; M P Zwiers; D J Heslenfeld; D van der Meer; B Franke; J Oosterlaan; J K Buitelaar; P J Hoekstra
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-11-14       Impact factor: 4.785

2.  The value of observational cohort studies for cancer drugs.

Authors:  David R Spigel
Journal:  Biotechnol Healthc       Date:  2010

3.  The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system.

Authors:  Christian G Reich; Patrick B Ryan; Marc A Suchard
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

Review 4.  The role of observational studies in optimizing the clinical management of chronic myeloid leukemia.

Authors:  Michael J Mauro; Catherine Davis; Teresa Zyczynski; H Jean Khoury
Journal:  Ther Adv Hematol       Date:  2015-02

5.  What's new in trial design: propensity scores, equivalence, and non-inferiority.

Authors:  Paul S Myles
Journal:  J Extra Corpor Technol       Date:  2009-12

Review 6.  What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?

Authors:  Cheryl A Oncken; H R Kranzler
Journal:  Nicotine Tob Res       Date:  2009-08-28       Impact factor: 4.244

7.  Factors associated with site requirement for glaucoma clinical trials.

Authors:  William C Stewart; Christina M Demos; Meredith Turner; Jeanette A Stewart
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-16       Impact factor: 3.117

Review 8.  Risk factors for subject withdrawals in clinical trials evaluating glaucoma medications.

Authors:  William C Stewart; Christina M Demos; Meredith K Turner; Jeanette A Stewart
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-09       Impact factor: 3.117

Review 9.  Utilization of health care databases for pharmacoepidemiology.

Authors:  Yasuo Takahashi; Yayoi Nishida; Satoshi Asai
Journal:  Eur J Clin Pharmacol       Date:  2011-08-02       Impact factor: 2.953

10.  Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study.

Authors:  Maurizio Margaglione; Emilia Antonucci; Giovanna D'Andrea; Ludovica Migliaccio; Walter Ageno; Eugenio Bucherini; Benilde Cosmi; Anna Falanga; Giuliana Martini; Daniela Mastroiacovo; Carmelo Paparo; Daniela Poli; Sophie Testa; Gualtiero Palareti
Journal:  Blood Transfus       Date:  2020-09-18       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.